Patents by Inventor Zehra Kaymakcalan

Zehra Kaymakcalan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170158758
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 22, 2016
    Publication date: June 8, 2017
    Applicant: AbbVie, Inc.
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew HERIGSTAD, Hong YANG, Kartik SUBRAMANIAN, Xiaobei ZENG, Diane D. DONG, Wen Chung LIM, Kathreen A. GIFFORD, Zehra KAYMAKCALAN, Christopher CHUMSAE
  • Publication number: 20170121403
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 16, 2016
    Publication date: May 4, 2017
    Applicant: AbbVie, Inc.
    Inventors: Kartik SUBRAMANIAN, Mayda Perez THIELE, Xiaobei ZENG, Chee Furng WONG, Zehra KAYMAKCALAN, Ying JING, Christopher M. CHUMSAE
  • Patent number: 9522953
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 20, 2016
    Assignee: ABBVIE, INC.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9499616
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 22, 2016
    Assignee: ABBVIE INC.
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Zehra Kaymakcalan, Ying Jing, Christopher M. Chumsae
  • Publication number: 20160237150
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: October 27, 2015
    Publication date: August 18, 2016
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Zehra Kaymakcalan, Ying Jing, Christopher M. Chumsae
  • Publication number: 20160194390
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: January 28, 2016
    Publication date: July 7, 2016
    Applicant: AbbVie, Inc.
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew Omon HERIGSTAD, Hong YANG, Kartik SUBRAMANIAN, Xiaobei ZENG, Diane D. DONG, Wen Chung LIM, Kathreen A. GIFFORD, Zehra KAYMAKCALAN, Christopher CHUMSAE
  • Patent number: 9321846
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 9315574
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: April 19, 2016
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9266949
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 23, 2016
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9200069
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9200070
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9181337
    Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: November 10, 2015
    Assignee: AbbVie, Inc.
    Inventors: Kartik Subramanian, Mayda Perez Thiele, Xiaobei Zeng, Chee Furng Wong, Zehra Kaymakcalan, Ying Jing, Christopher Chumsae
  • Publication number: 20150259410
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: May 15, 2015
    Publication date: September 17, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9085618
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimxental, are also provided.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: July 21, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Publication number: 20150175694
    Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Applicant: ABBVIE INC.
    Inventors: Albert COLLINSON, George Avgerinos, Richard DIXON, Tariq GHAYUR, Zehra KAYMAKCALAN
  • Publication number: 20150166678
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Publication number: 20150166650
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: December 29, 2014
    Publication date: June 18, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew Omon HERIGSTAD, Hong YANG, Kartik SUBRAMANIAN, Xiaobei ZENG, Diane D. DONG, Wen Chung LIM, Kathreen A. GIFFORD, Zehra KAYMAKCALAN, Christopher CHUMSAE
  • Publication number: 20150140006
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: February 4, 2015
    Publication date: May 21, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Publication number: 20150132320
    Abstract: The present invention is directed to modified antibodies, including anti-TNF? antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
    Type: Application
    Filed: December 15, 2014
    Publication date: May 14, 2015
    Inventors: Chris M. Chumsae, Zehra Kaymakcalan